Davis Polk advised the underwriters in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on Rule 144A and Regulation S of Akeso, Inc. The net proceeds from the offering amounted to approximately HK$2.44 billion ($312 million) prior to the exercise of the over-allotment option.

Akeso, Inc. is a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies. It is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. Its vision is to become a global leader in developing, manufacturing and commercializing innovative, next-generation and affordable therapeutic antibodies for patients worldwide.

The Davis Polk corporate team included partners Li He, Yang Chu and James C. Lin, counsel Stephenie Fung, counsel - registered foreign lawyer Xuelin (Steve) Wang, associate Edwin Lee and registered foreign lawyer Xiushan Sun. Counsel Alon Gurfinkel and associates Omer Harel and Summer Xia provided tax advice. Members of the Davis Polk team are based in the Hong Kong and London offices.

Copy link to share post